The highly potent API (HPAPI) sector is one of the fastest growing areas in the pharmaceutical industry; the annual revenue from these drugs is expected to reach a value of $40 billion in 2025.1
More than a quarter of drugs on the market today are classed as highly potent and the contract manufacturing market for HPAPIs is expected to grow at a CAGR of 10.1% through to 2027.2,3
Although the market for HPAPIs is largely in oncology, they also used in a range of applications including asthma, diabetes and cardiovascular diseases.
Nearly a third of new drug approvals during the past few years have been for cancer and 60% of oncology drugs currently in development involve highly potent ingredients, emphasising the importance of the sector’s ability to handle and manufacture these products.1,4